Page 111 - Haematologica Vol. 109 - July 2024

ARTICLE - MUD versus haplo PT-CY stem cell transplantation in children with AML A. Ruggeri et al. Table 1. Patients and transplant characteristics.
Variables Modalities N=516 MUD N=420 Haplo PT-CY N=96 P N (%) N (%) N (%)
Age in years at HCT median (IQR) 8.5 (2.8-13.7) 7.7 (2.8-13.6) 9.8 (3-15.2) 0.03
Age in years at HCT 7-12
107 (20.7)
0-7 231 (44.8)
200 (47.6)
82 (19.5)
138 (32.9)
31 (32.3)
25 (26)
40 (41.7)
Not done
-
-
12-18 178 (34.5)
Disease status at HCT
CR1 366 (70.9) 296 (70.5) 70 (72.9) 0.63
CR2 150 (29.1) 124 (29.5) 26 (27.1) -
No 49 (15.6)
Molecular remission Yes 266 (84.4)
Missing 201
41 (15.9)
217 (84.1)
162
8 (14) 0.73
49 (86) -
39 -
Year of HCT
Median (IQR) 2017 (2014-2019) 2016 (2014-2018) 2018 (2017-2020) <0.001
Range 2011-2021 2011-2021 2011-2021 -
Parent - - 70 (83.3) Not done
Relation to donor Sibling - - 14 (16.7) -
Missing - - 12 -
Donor age in years
Median (IQR) 29.1 (23.8-36.3) 27.7 (23.3-34.2) 35.7 (29.5-42.7) <0.001
Missing 104 91 13 -
Cell source
BM 330 (64) 267 (63.6) 63 (65.6) 0.71
PB 186 (36) 153 (36.4) 33 (34.4) -
Patient sex
Female 242 (46.9) 197 (46.9) 45 (46.9) 0.99
Male 274 (53.1) 223 (53.1) 51 (53.1) -
Female donor to male recipient
No 434 (84.1) 365 (86.9) 69 (71.9) <0.001
Yes 82 (15.9) 55 (13.1) 27 (28.1) -
Lansky or KPS
<90 119 (23.1) 104 (24.8) 15 (15.6) 0.06
≥90 397 (76.9) 316 (75.2) 81 (84.4) -
CMV-IgG match (donor-recipient)
Neg to Neg
Neg to Pos
Pos to Neg
Pos to Pos
120 (23.3)
130 (25.2)
60 (11.6)
206 (39.9)
112 (26.7)
123 (29.3)
50 (11.9)
135 (32.1)
8 (8.3)
7 (7.3)
10 (10.4)
71 (74)
< 0.001
-
-
-
Cytogenetic risk
Good
Intermediate
Poor
Missing
66 (14.9)
199 (44.9)
178 (40.2)
73
50 (13.6)
163 (44.3)
155 (42.1)
52
16 (21.3) 0.09
36 (48) -
23 (30.7) -
21 -
CSA+MTX based
CSA based
GVHD prophylaxis CSA+MMF based
CSA+MMF+MTX based
Other
289 (56)
71 (13.8)
67 (13)
12 (2.3)
77 (14.9)
288 (68.6)
66 (15.7)
17 (4)
9 (2.1)
40 (9.5)
1 (1)
5 (5.2)
50 (52.1)
3 (3.1)
37 (38.5)
Not done
-
-
-
-
BuCyMel based
BuCy based
Conditioning regimen BuFlu based
Treo based
Other combinations
162 (31.4)
131 (25.4)
123 (23.8)
88 (17.1)
12 (2.3)
161 (38.3)
121 (28.8)
59 (14)
70 (16.7)
9 (2.1)
1 (1)
10 (10.4)
64 (66.7)
18 (18.8)
3 (3.1)
Not done
-
-
-
-
MUD: matched unrelated donors; haplo: haploidentical; PT-CY: post-transplant cyclophosphamide, HCT: hematopoietic stem cell transplan- tation; IQR: interquartile range; CR: complete remission; BM: bone marrow; PB: peripheral blood; KPS: Karnofsky Performance status, CMV: cytomegalovirus; GVHD: graft-versus-host disease; CSA: cyclosporin; MTX: methotrexate, MMF: mycophenolate mofetile; Bu: busulfan, Flu: fludarabine; Cy: cyclophosphamide; Mel: melphalan; Treo: treosulfan; Pos: positive; Neg: negative.
Haematologica | 109 July 2024
2125